Australian Particle Therapy Clinical Quality Registry


Australian Particle Therapy Clinical Quality Registry (ASPIRE) is a prospective, observational, longitudinal study of paediatric, adolescent, young adult and rare adult tumour patients from a select group of tumour streams treated with radiation therapy. Comparing the long-term toxicities of photon and proton radiation therapy.

For more about ASPIRE visit: https://www.protontherapy.sahmri.org.au/about-aptcqr/

Primary Sponsor

South Australian Health & Medical Research Institute (Australian Bragg Centre for Proton Therapy and Research)

Collaborating Groups

TROG Cancer Research

Trial Chairperson

A/Prof Hien Le, Royal Adelaide Hospital, SA

Trial Contact

ASPIRE@sahmri.com

Clinical Trial Registration

Related Post

11 June, 2025

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer

LATEST NEWS: 11 JUNE 2025 New findings from a

Grant for PRIME-Lung trial
10 June, 2025

MRFF $1.5m grant for TROG-sponsored trial of new approach in lung cancer

LATEST NEWS: 10 JUNE 2025 A trial of a